Drug Profile
Research programme: RNAi therapeutics - Boehringer Ingelheim/Dicerna Pharmaceuticals
Alternative Names: DCR-LIV1Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Dicerna Pharmaceuticals
- Developer Boehringer Ingelheim; Dicerna Pharmaceuticals
- Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Hepatoprotectants; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-alcoholic steatohepatitis
- No development reported Liver disorders
Most Recent Events
- 03 Jan 2024 RNAi therapeutics is still in research phase for Non-alcoholic steatohepatitis in Germany
- 03 Jan 2024 Boehringer Ingelheim, Ribocure Pharmaceuticals, and Suzhou Ribo Life Science entered in to a R&D agreement to develop RNAi therapeutics
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk